A federal judge in Louisiana has granted a request from the Food and Drug Administration (FDA) to temporarily pause a lawsuit challenging the agency’s 2023 rule allowing mifepristone to be prescribed via telehealth and dispensed by mail. The case, Louisiana v. FDA, centers on a legal challenge to the federal regulations governing access to the medication, which is used for first-trimester abortion and miscarriage management.
The following report synthesizes information from multiple sources regarding the legal status of mifepristone, trends in abortion access, and ongoing policy developments.
Legal Proceedings and Ruling
Judge David C. Joseph of the U.S. District Court in Louisiana issued a 37-page ruling on Tuesday, declining to immediately alter national access to the medication. The judge determined that the FDA, as the agency with scientific expertise, should be allowed to complete its own safety review of mifepristone before the court proceeds with the case. The FDA requested the stay in order to evaluate the scientific evidence and make a public health judgment. The judge ordered the FDA to update the court on its review progress within six months.
The state of Louisiana, along with a Louisiana patient identified as Rosalie Markezich, is the primary plaintiff in the lawsuit.
The complaint, filed in October, alleges that the FDA’s 2023 rule change was intended to facilitate the mailing of mifepristone into states with abortion bans, thereby causing harm to Louisiana and certain individuals. The FDA is the defendant, and the drug manufacturers GenBioPro and Danco Laboratories have been permitted to intervene to defend their medications. The judge ruled that the state of Louisiana has legal standing to pursue the case.
This case follows a separate legal challenge to mifepristone access that was unanimously rejected by the U.S. Supreme Court in 2024. In May 2026, a federal appeals court panel had briefly restricted access to mifepristone, requiring in-person prescriptions nationwide, but the Supreme Court restored access while litigation continues.
Timeline of Key Legal Events
- 2023: FDA revises regulations for mifepristone, removing the requirement for an in-person appointment and allowing telehealth prescriptions and mail delivery.
- 2024: U.S. Supreme Court unanimously rejects a separate challenge to mifepristone access.
- October 2025: Louisiana files a lawsuit against the FDA challenging the 2023 rule change.
- May 2026: A federal appeals court panel briefly orders in-person prescription requirements for mifepristone; the Supreme Court restores access pending ongoing litigation.
- Current: Federal judge stays the case for up to six months, allowing the FDA to conduct a safety review.
Impact on Abortion Access and Numbers
According to data from the Guttmacher Institute, an organization that supports abortion access, the number of clinician-provided abortions in the U.S. has remained stable despite state-level restrictions enacted since the 2022 reversal of Roe v. Wade. The institute estimated approximately 1,126,000 abortions were provided in the U.S. in 2025, a figure largely unchanged from 2024.
The Society of Family Planning’s #WeCount report found that the number of abortions in the U.S. nearly doubled from 2021 to 2025, with 29% of abortions in December 2025 occurring via telehealth.
Regional Data
- National: Abortion numbers did not decrease after the Supreme Court overturned Roe v. Wade in 2022. In 2023, approximately 1.1 million abortions were provided, consistent with the prior year.
- Louisiana: Abortions in the state increased from approximately 2,500 in 2022 to over 9,000 in 2023.
- Patients in states with bans: Roughly 91,000 patients residing in states with abortion bans received telehealth abortions in 2025.
Role of Telemedicine and Shield Laws
Telemedicine has become a key method for maintaining abortion access. The FDA's 2023 regulatory change allowed mifepristone to be prescribed without an in-person appointment. Some states with laws protecting abortion access have implemented "shield laws," which are designed to protect healthcare providers from legal risks when prescribing medication to patients living in states with abortion bans. This has led to an increase in individuals in states with restrictions accessing abortions via telemedicine.
Medication Protocols and Availability
Mifepristone, used in combination with misoprostol, has been available in the U.S. for over 25 years for first-trimester abortion and miscarriage management. The medication is considered safe and effective by the medical community.
Two-Drug Regimen (Mifepristone + Misoprostol)
- FDA-approved: Up to 10 weeks of pregnancy.
- WHO-endorsed: Up to 12 weeks of pregnancy.
- Current status: This regimen remains available for in-person patients in states where abortion is legal. Telehealth prescriptions and mail delivery are currently allowed, pending the outcome of the Louisiana lawsuit.
Misoprostol-Only Protocol
- Misoprostol, which is also used for ulcer prevention, is more widely stocked in pharmacies due to its other medical uses.
- The protocol involves taking misoprostol every 3 hours for 3–4 doses; the pregnancy typically passes in 9–12 hours.
- Research indicates that misoprostol-only abortions are as safe as the two-drug regimen. The American College of Obstetricians and Gynecologists and the World Health Organization consider this protocol safe and effective.
- Side effects may include more nausea, vomiting, diarrhea, longer bleeding, and cramping compared to the two-drug regimen.
- Gestational limits: Some studies indicate misoprostol alone can be effective up to 22 weeks; doctors in states allowing second-trimester abortions typically recommend procedural abortion after 12 weeks.
- Providers have prepared to switch to misoprostol-only regimens if mifepristone access is restricted.
Advance Provision
A Planned Parenthood affiliate, Planned Parenthood Great Northwest, Hawai'i, Alaska, Indiana and Kentucky, has begun offering advance provision of abortion medications (mifepristone and misoprostol) to patients in Washington and Hawaii. The program, called "Just In Case Abortion Pills," allows individuals to obtain the pills before pregnancy for potential future use. Patients can receive the medication via telehealth or in person at 16 health centers. The pills have a shelf life of approximately two years.
Legal and Regulatory Landscape
State-Level Actions
- Louisiana: Has classified mifepristone and misoprostol as controlled substances. The state has also pursued criminal charges against an out-of-state physician for providing telemedicine abortion.
- Texas: Allows private lawsuits against out-of-state prescribers of abortion pills, with a statutory penalty of $100,000.
- Controlled Substances: The medications are legal to possess in 49 states; Louisiana classifies the drugs as controlled substances.
Federal Powers and Legislation
- Comstock Act: Anti-abortion advocates are advocating for enforcement of this 19th-century law, which could prohibit the mailing of abortion-related materials and potentially create a de facto national ban without new legislation.
- Congressional action: A Republican-led Congress cut Planned Parenthood from Medicaid funding for one year, with reinstatement scheduled for July 2025.
- Trump administration: Has taken limited action on abortion medication.
Patient Experience
Patients seeking abortions in states with restrictions have used various methods to obtain medication. In one reported example, a 27-year-old woman in Georgia, following the state's six-week ban, obtained abortion medication through a Massachusetts-based group, which shipped the medication to her home. The process involved an online questionnaire and a fee based on affordability.
Political and Public Response
Campaign Advertising and Election Focus
According to data on campaign advertising, Democratic candidates in House and Senate races spent more on ads mentioning abortion than on any other issue in the 2022 and 2024 elections. Since January 2026, candidates have spent almost four times less on campaign ads about abortion compared to the same period in 2024. Voters consistently rank cost-of-living concerns as their top issue.
Statements from various candidates and advocates reflect differing perspectives on how to address the issue. Democratic Senate candidate Graham Platner (ME) argued that affordability is central to reproductive access. Rep. Angie Craig (D-MN) said that economic concerns are front and center for voters but noted that reproductive rights are also an economic issue.
Opposition and Criticism
Opponents of abortion access have expressed concerns regarding the expansion of telehealth abortion. Senator Cindy Hyde-Smith (R-MS) criticized advance provision of abortion pills as "stockpiling" with insufficient oversight. Kristi Hamrick of Students for Life of America described misoprostol-only regimens as riskier and called for continued pressure on the Trump administration. Gabriella McIntyre of Alliance Defending Freedom argued that restricting mail-order mifepristone would reduce abortions nationwide.
FDA Commissioner Statement
During a 2024 hearing, FDA Commissioner Robert Califf stated that the agency does not advocate stockpiling but does not regulate the practice of medicine.
Outlook
The U.S. Supreme Court has temporarily maintained current access to mifepristone while litigation in Louisiana v. FDA continues. Kelly Baden of the Guttmacher Institute stated that abortion policy remains unsettled and will likely be on the ballot in upcoming elections.